PRM44 A Virtual Database To Measure Costs Associated With Comorbidities Among Patients With Chronic Hcv  by Kawabata, H. et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A17
PRM41
Validity Of Medicaid analytic extRact (Max)-2009, OutPatient (Ot) 
and PROVideR chaRacteRistics (Pc) data fOR use in Mental health 
ReseaRch
Medhekar R., Chen H.
University of Houston, Houston, TX, USA
Objectives: To assess the validity of Medicaid Analytic Extract (MAX)-2009, 
Outpatient (OT) and Provider Characteristics (PC) data for use in mental health 
research. MethOds: Medicaid issue briefs, Medicaid managed-care enrollment 
report, MAX-PC evaluation reports and MAX-validation tables for the year 2009 were 
reviewed to assess the validity of MAX-OT and MAX-PC data. Validity of the data was 
defined in terms of availability [OT: substantial number of encounter claims; PC: 
substantial number of OT billing/servicing provider IDs], completeness [OT: number 
of claims per PME, % enrollees with encounter record, number of claims per service 
user; PC: % provider IDs with primary taxonomy code] and usability [OT: primary 
diagnoses and/or procedure code reported per record]. Each state was ranked on 
these criteria as 1: Good, 2: Fair and 3: Poor for both OT and PC data and a total 
combined-score was calculated. The states with minimum total combined-score, 
which met all the criteria, were considered appropriate for research. Results: 
Thirty-six states delivered some/all mental health services through managed care 
organizations (MCOs) and the rest relied on fee-for-service (FFS). Eleven states con-
tracting with comprehensive MCOs, 4 states contracting with behavioral health 
organizations (BHOs), and 6 FFS states have usable OT-encounter data. PC data was 
available for all 51 states, of which 15 states have usable data with > 90% claims 
with OT billing/servicing provider IDs. Twelve of these states have data with ≥ 75% 
provider IDs with primary taxonomy codes. Three comprehensive MCO states (KY, 
NJ, NY), 2 BHO states (AZ, FL) and 2 FFS states (MS, LA) met all the validity criteria 
for OT and PC files. cOnclusiOns: Although, most states provide mental health 
services through comprehensive MCOs, OT-encounter data for these services is 
usable for limited states only. Researchers should exercise caution while combining 
OT and PC files for mental health research.
PRM43
deVelOPMent Of a database Of Published RegulatORy 
RecOMMendatiOns cOnceRning the use Of clinical OutcOMe 
assessMent (cOas) in dRug deVelOPMent: OutcOMes insite
Perret C.1, Roborel de Climens A.2
1Mapi Research Trust, Lyon, France, 2Mapi, Lyon, France
Objectives: As defined by the FDA, a Clinical Outcome Assessment (COA) directly 
or indirectly measures how patients feel or function and can be used to determine 
whether or not a drug has demonstrated to provide a treatment benefit. There are 
four types of COAs: patient-reported (PRO), observer-reported (ObsRO), clinician-
reported (ClinRO), and performance outcomes (PerfO). The aim of this research is 
to create an online database of published regulatory recommendations concerning 
the use of COAs to determine treatment benefit and to inform drug approval and 
health technology assessment (HTA) review. MethOds: All clinical guidelines pub-
lished from 1977 to 2014 by North American regulatory authorities (FDA and Health 
Canada), the European Union (EMA), and NICE, were retrieved on the corresponding 
websites and reviewed. The information was categorized as follows: guideline title, 
date of publication, guideline status (“draft” or “final/adopted”), therapeutic area and 
indication based on ICD -10 classification, guideline purpose(s), and for each COA, 
the concept of interest and context of use (e.g., targeted patient population, endpoint 
positioning and study design). Results: For the EMA, we reviewed 110 scientific 
guidelines representing 62 therapeutic indications, of which approximately more 
than half recommend COA endpoints. For the FDA, we analyzed 86 guidance repre-
senting 56 therapeutic indications, of which almost 60% recommend COA endpoints. 
For Health Canada, five guidance representing five therapeutic indications were 
retrieved. The 96 recommendations published by the NICE correspond to 75 thera-
peutic indications, and are currently under review. cOnclusiOns: This project will 
be a unique source of centralized information about how COAs are recommended 
by regulatory authorities in drug development and HTA review. It will be useful to 
observe the current trends in COAs recommended, and to integrate them as early 
as possible in the product development. The database will be available online in an 
independent website, with access by subscription.
PRM44
a ViRtual database tO MeasuRe cOsts assOciated With cOMORbidities 
aMOng Patients With chROnic hcV
Kawabata H.1, Behl A.1, Hines P.1, Liu T.1, Sill B.1, Hede S.1, Gorsh B.1, Moorthy V.2
1Bristol-Myers Squibb, Plainsboro, NJ, USA, 2Mu Sigma, Northbrook, IL, USA
Objectives: Healthcare resource utilization and costs are often measured by ret-
rospective claims analyses. Using a common data model (CDM) with standardized 
variables has the ability to enhance robustness and generalizability of data and 
improve the timeliness of these studies. Given the rapidly changing treatment land-
scape for HCV, it is a prime candidate for research based on a CDM. The purpose of 
this study was to analyze healthcare resource use and costs by comorbidity status 
in patients with chronic HCV using a virtual database based on a CDM. MethOds: A 
virtual database was created with 3 large commercially available datasources using 
specifications developed by Observational Medical Outcomes Partnership (OMOP) 
CDM v4 format (www.omop.org/CDM). By employing a massively parallel processing 
(MPP) database platform we created this database with 30+ standardized variables 
as needed for this study. Utilizing this virtual database allowed for comparison of 
demographic, clinical, and healthcare utilization variables analyzed simultaneously 
across the large databases for patients with HCV. Results: Results from two of the 
databases (1 commercial/Medicare, 1 commercial only) representing more than 
212,000,000 covered lives yielded information for 97,935 patients with chronic HCV 
(n= 46,384 for database 1; n= 51,551 for database 2). Baseline demographics were 
similar between the databases. Slightly less than 10% of patients had compensated 
cirrhosis, approximately 5% had decompensated cirrhosis, and transplant percent-
were identified using a validated questionnaire. The direct medical costs of patient 
management were estimated using a micro-costing analysis, and a sensitivity analy-
sis conducted using the emergency room visits rates due to DRM reported in the 
literature. All costs are presented in 2014 US$ (US$1= R$2.70). Results: 14.6% of 
patients sought emergency care due to DRM; 58.9% of DRMs were considered pre-
ventable. Mean treatment costs were US$812.38 ± 1,417 (range US$16.04 to 9,832). 
Mean inpatient length of stay of DRM patients was (5.7 ± 8.4 days). An extrapolation 
based on all 57.106 emergency visits in the last year resulted in annual total treat-
ment costs of US$6.773 million. A sensitivity analysis resulted in US$1.043 million 
in the best-case scenario and US$12.989 milion at worst, per year. cOnclusiOns: 
This is one of the first analyses of the economic consequences of DRM in Brazil, and 
shows that DRMs leading to emergency visit and hospital admission are common 
and constitute a significant economic impact to the hospital. Efforts are necessary 
to improve pharmacotherapy and reduce preventable iatrogenic costs.
ReseaRch On MethOds – databases & Management Methods
PRM39
is the PReValence Of alzheiMeR’s disease undeRestiMated? 
cOMPaRisOns and cOntRasts Of diffeRent aPPROaches in estiMating 
alzheiMeR’s disease
Yuan J., Lu K.
University of South Carolina, Columbia, SC, USA
Objectives: Estimating the prevalence of Alzheimer’s disease (AD) has been a chal-
lenge because it has been relying on self/proxy-reported information or based on 
diagnosis alone, yielding inconsistent and underestimated results in the published 
studies. The objective of this study was to provide a more accurate prevalence of AD, 
and to make comparisons and contrast of different approaches in ascertain demen-
tia. MethOds: A cross-sectional study was performed using the Medicare Current 
Beneficiary Survey (MCBS) 2010. The study sample consisted of Medicare beneficiar-
ies aged 65 or older. AD was ascertained by using self/proxy’s report, ICD-9-CM diag-
nosis codes in the Medicare claims; AD-targeted prescription medications identified 
from both self/proxy’s report and pharmacy claims, or using a combined sources 
of information. Prevalence was estimated using ross-sectional weights. Weighted 
Kappa coefficients were estimated. Results: The prevalence of AD varied greatly 
by using different sources of information. The prevalence of AD was dropped from 
6.8% when using a combined methodology, to 3.5% when using self/proxy’s report 
alone, 1.4% when using claims data alone, and 5.3% when based on the utilization of 
AD-target medications. Using data from AD-target medications (78%) captured more 
AD cases than using self-reported data alone (52%) and claims only (21%), which 
was observed in both community and long-term care facilities. These discrepancies 
in describing AD cases were significant. The agreement between AD-target medica-
tions and claims data was 30.7% (kappa= 0.28), 38.4% between AD-target medications 
and self/proxy’s report (kappa= 0.49), and 47.2% between self/proxy-reported and 
AD-target medications (kappa= 0.27).Compared to pharmacy claims, self-reported 
medication use provided slightly higher estimates of AD cases (48.5% vs. 40.8%; 
kappa= 0.26). cOnclusiOns: The prevalence of AD was largely underestimated by 
using self/proxy’s report or claims alone. Our findings have important implications 
for identifying AD cases, and suggested a better algorism of capturing AD. Further 
research is warranted to validate the algorisms to identify AD cases.
PRM40
unified database cReatiOn aPPlied tO Public bRazilian health 
infORMatiOn systeMs fROM the hOsPital, OutPatient and MORtality 
infORMatiOn systeMs
Pereira R.G.1, Leal G.S.2, Silva L.V.3, Andrade E.I.1, Acurcio F.d.2, Cherchiglia M.L.1,  
Guerra Junior A.A.2
1Federal University of Minas Gerais, Belo Horizonte, Brazil, 2College of Pharmacy, Federal 
University of Minas Gerais, Belo Horizonte, Brazil, 3Faculdade Promove, Belo Horizonte, Brazil
Objectives: Unify and deterministically deduplicate databases’ of patients regis-
tration information coming from Information Systems of SUS in Brazil: Hospital, 
Output and Mortality Information Systems, between the years 2000-2012, to get 
an individualize data and plot patients’ lines of care during the period, enabling 
pharmacoeconomic and epidemiological studies that parameterize effectiveness 
and efficiency of public policies and embedded technologies. MethOds: Semantic 
analysis of data was performed to describe and understand different meanings 
of different fields existing in the studied bases. In addition, there were two main 
procedures, executed with database operations tools and PLSQL programming lan-
guage: cleaning and standardization of databases; registration information extrac-
tion and deterministic deduplication thereof. Both procedures were first performed 
on each database separately and after the unification of the records, was held again 
a deterministic deduplication. Results: Performed procedures allowed a decision-
making to chose fields used in data model for the unified database creation. Five 
database’s representative fields related to patients were selected: first name and 
last name; birth date; state and country code of residence. Initially, the unified 
cadastral database resulted in 570,649,706 records, after deduplication there was a 
reduction culminating in 106,433,845 records. This reduction is explained because 
these databases are not fully integrated. Moreover, there is not always agreement 
between semantic systems and in some cases changes occur in the data format 
over the period within the same system. cOnclusiOns: The results show that 
data deduplication is necessary and should be carried out thoroughly. Where the 
databases had limited patients’ registration information, the technique enabled to 
capture, in more complete basis, additional information. Futhermore, it allowed to 
identify and assist in the understanding of positive and negative aspects within 
systems and trace clinical condition of patients, enabling pharmacoeconomic and 
epidemiological studies that define effectiveness and efficiency of public policies 
and embedded technologies. As future work, is important ensure the univocity of 
records.
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once candidates were identified, all recruitment efforts could be directly targeted 
to specific patients as opposed to advertising to a large, undefined population or 
relying on physician referral. This resulted in improved patient response rates, 
which could conceivably be improved further with the creation of more targeted 
recruitment materials developed by patient demographic profiles generated from 
EMR data.
PRM48
cOMPaRatiVe landscaPe assessMent Of us healthcaRe databases fOR 
use in health ecOnOMics MOdeling
Wehler E.A.1, Donga P.1, Munakata J.2
1IMS Health, Plymouth Meeting, PA, USA, 2IMS Health, San Francisco, CA, USA
Objectives: Real world evidence (RWE)-based tools are important to fill data 
gaps and capture real world cost and treatment patterns in economic modeling. 
The objective of this study was to assess the capabilities of US-based longitu-
dinal, retrospective data assets to inform health economic models in diabetes 
and oncology. MethOds: To illustrate the availability of RWE data for modeling, 
several IMS data assets were compared in a landscape assessment, including 
Pharmetrics Plus (PMTX+), Oncology Electronic Medical Record (EMR), Ambulatory 
EMR, Charge Data Master (CDM), Pharmacy (LRx), Office Based Medical Claims 
Data (Dx), and Laboratory Data (Labs). Diabetes and oncology were chosen to 
illustrate the range of needed inputs across commonly modeled diseases. Data 
availability was assessed in a matrix framework across core categories of model 
inputs including: treatment patterns, epidemiology, adverse events (AEs), patient 
health metrics (i.e., BMI), costs, resource use, and disease status. Results: For 
oncology, inputs for treatment patterns (PMTX+, Oncology EMR), epidemiology 
(PMTX+, Oncology EMR, CDM), AEs (PMTX+, Oncology EMR, CDM), and resource 
use (PMTX+, Oncology EMR) are available in several data assets but information 
on patient health metrics and disease status may require leveraging the Oncology 
EMR database to capture sufficient detail. For diabetes, availability of data for 
populating models is more robust increasing information on treatment patterns 
(PMTX+, LRx linked to Dx), epidemiology (PMTX+, Ambulatory EMR, CDM), resource 
use (PMTX+, Labs, Dx), AEs (PMTX+, Ambulatory EMR, CDM, Dx), and patient health 
metrics (Ambulatory EMR, CDM). While several databases report cost outcomes, 
the most relevant costs for modeling are found in PMTX+. cOnclusiOns: Core 
concepts for economic modeling can be populated with RWE assets in the US 
though no single database is likely to cover all inputs. The choice of data should 
be informed by the research question, patient counts and the ability to link 
databases.
PRM49
Validity and liMitatiOns Of the lOngitudinal Patient 
database fRance fOR use in PhaRMacOePideMiOlOgical and 
PhaRMacOecOnOMics studies
Jouaville S.L., Miotti H., Coffin G., Sarfati B., Meihoc A
Cededim Strategic Data, Boulogne-Billancourt, France
Objectives: Longitudinal Patients Database (LPD) is a primary care database of 
anonymized electronic medical records (EMR) from about 4 % of the French popu-
lation. Diagnosis and prescription data are routinely collected from proprietary 
practice management software used by physicians (primary care and specialists) 
to maintain EMR of their patients. Although LPD has been extensively validated 
by numerous publications and its use by French National Health Authorities, this 
is the first time that its representativeness and validity is systematically exam-
ined. MethOds: The distribution of several variables were analyzed and compared 
to available literature. Part of these variables refers to physician’s practices partici-
pating to the database while others refer to patients in these practices. Data about 
prevalence, treatments, and patients profile were retrieved from published French 
Health Authorities studies based on LPD data and compared to other published 
sources. Results: The sampling methods for the physician’s selection practices 
were shown to provide a good representativeness of the physician panel. Analyze 
of the patients population showed that LPD included all the subsets of the French 
general population, although pediatrics were underrepresented. Prevalences of 
several illnesses (diabetes, asthma, atrial fibrillation, aortic aneurism), treatments 
(dyslipidemia, diabetes), patients’ profiles (dyslipidemia, atrial fibrillation, venous 
disease) were in agreement to those encountered in literature. However, smok-
ing status, hospitalizations, referral to specialists were only partially reported and 
no information was available about sociodemographic status or death of patients. 
The availability of missing information through the use of questionnaires/pop up 
screens for physicians and patients, and the linkage of the EMR database to a claims 
database (HEAD) is also documented. cOnclusiOns: We found no indications of 
lack of representativeness or validity of the LPD. While presenting some flaws asso-
ciated with its naturalistic nature, LPD is a good support for pharmacoepidemiologi-
cal and pharmacoeconomics studies.
PRM50
lack Of adheRence tO iMMunOsuPPRessiVe tReatMent in kidney 
tRansPlant Patients: cOMPuteR assisted QualitatiVe data analysis 
(caQdas) Of an exPeRt Panel
Callejo D.1, Rodríguez-Aguilella A.1, Fernández-Ortiz L.1, González E.2, Toledo A.2, Rebollo P.1, 
Muduma G.3
1Laser Analytica, Oviedo, Spain, 2Astellas Pharma SA, Madrid, Spain, 3Astellas Pharma EMEA, 
Chertsey, UK
Objectives: To investigate the risk of Chronic Humoral Rejection (CHR) due to Lack 
of Adherence to Immunosuppressive Treatment (LAIT) in Kidney Transplant (KT) 
patients using Computer Assisted Qualitative Data Analysis (CAQDAS). MethOds: 
A systematic literature review was conducted using Medline, Psycinfo and BVS to 
identify studies published between 2009 and 2013 on CHR due to LAIT in KT patients. 
Based on this review a questionnaire was developed focussing on the information 
gaps identified. Six physicians from major Spanish Transplant centres then com-
ages ranged from 0.83% to 2% respectively. All-cause healthcare Per Patient Per Year 
costs were approximately $13,200 in each database. cOnclusiOns: Creation of a 
database using a CDM approach allows for simultaneous examination of standard-
ized claims across databases, thus broadening the efficiency and generalizability of 
retrospective claims analyses. The diverseness of comorbidities among HCV patients 
combined with the evolving treatment landscape makes it an ideal candidate for 
this type of research.
PRM45
big data in eMeRgency dePaRtMent caRe deliVeRy: benefits Of RadiO 
fReQuency identificatiOn
Benkhadra K., Sir M., Nestler D., Hellmich T., Pasupathy K.
Mayo Clinic, Rochester, MN, USA
Objectives: Lack of a coordinated primary care system is forcing individuals to 
seek emergency departments (EDs) as gateway into the health system. As volumes 
increase and cases become more complex, combined with inadequate downstream 
capacity lead to boarding, bottlenecks and wait times. The goal was to review ben-
efits of Radio Frequency identification (RFID) demonstrated in the literature in the 
ED. MethOds: Article searches were conducted and they were categorized based 
on benefits in three areas: patients, staff, assets. Results: Evidence of use of RFID 
in ED went as far back as 2006 with both domestic and international applications 
mostly using active technology. Majority of the articles demonstrated reducing 
wait times in the ED. One of the articles in turn demonstrated impact on patient 
satisfaction. Reduction in wait times were demonstrated when admitting patients 
into ICU from the emergency setting. In case of staff, use of RFID demonstrated 
increased satisfaction in a pediatric emergency setting. Evidence also exists in bet-
ter tracking of assets and equipment in the ED. Very little evidence of use of RFID 
in simulation and analytical models exist. Most of the studies were retrospective 
in nature. Wait times and asset tracking are tangible benefits with direct impact on 
return-on-investment. cOnclusiOns: RFID has been used is various settings in 
healthcare and quality benefits have been demonstrated. Lesser evidence of RFID 
use in the ED exists. RFID benefits have primarily been demonstrated with regard 
to wait times and asset tracking and management. Patient and staff satisfaction 
are more intangible benefits. As EDs start to reap benefits with wait times, use in 
simulation and advanced analytical models could potentially inform workload, 
team configuration and team dynamics studies. As healthcare moves into the 
era of big data, live streaming RFID data can be tapped for real-time decision 
making.
PRM46
Why PeeR-ReVieW JOuRnals ReJect Real-WORld and health-ecOnOMic 
PaPeRs
Hartog T.E.1, Peters K.2, Diamond M.1, Nuottamo N.1
1Excerpta Medica, Amsterdam, The Netherlands, 2Excerpta Medica, London, UK
Objectives: To evaluate the most common reasons provided by peer-reviewed 
journals to reject manuscripts describing data derived from real-world or health-
economic (RW/HE) studies. MethOds: Our company project administration 
records from the last 10 years were reviewed for manuscripts describing HE stud-
ies, RW/observational studies (including retrospective database analyses), and 
patient or disease registries. Reasons for rejection were collected and stratified 
into “categories”. If more than one reason was provided by the journal, then all 
reasons were counted. Our analysis was based on industry-sponsored manuscripts 
for which a complete submission history was available. Results: Rejection let-
ters were collected for 78 manuscripts. Of these, 12 did not specify a reason for 
rejection. The remaining records revealed a total of 100 rejection counts. The most 
common reasons were ‘priority rating not high enough’ (33%), ‘concerns about the 
methodology’ (18%), and ‘information not sufficiently novel’ (15%). Other reasons 
for rejection included ‘topic not appropriate for the journal’ (7%), ‘manuscript is 
biased/conclusions are too strong’ (5%), ‘industry involvement not sufficiently 
disclosed’ (2%), and referral to a sister journal instead (2%). cOnclusiOns: 
These common reasons for rejection could provide authors with some guidance 
on which factors are particularly important to focus on during the development of 
a RW/HE manuscript to help improve the chances of acceptance by peer-reviewed 
journals.
PRM47
utilizing electROnic Medical RecORd netWORks fOR identifying 
Patients fOR clinical tRial RecRuitMent
Spencer J., Wilson A., Bailey N., Longson M.S., Kamauu A.
Anolinx, Murray, UT, USA
Objectives: Much of the increase in health-care expenses in the U.S. can be 
traced to the development of new drug therapies; with the average discovery 
and development process costing over $1.4 billion per drug. This motivates the 
need to reduce drug costs through more efficient drug development and testing, 
specifically, by streamlining clinical trials. The current study aims to implement 
and evaluate a process, using a data driven approach, to recruit patients for a 
clinical trial for an asthma treatment. Our hypothesis is that recruitment could 
be improved and accelerated with the support of an EMR network to identify 
patients. MethOds: All trial protocol eligibility criteria were reviewed in the con-
text of EMR data availability, as well as protocol-specific procedures. We then que-
ried our EMR network to identify sites with high patient concentrations. Four sites 
were recommended to the team by partners in this network and selected, with 
one site opting not to participate in the study after being selected. Results: EMR 
queries identified over 300 potentially eligible patients at three different sites. Of 
identified patients who were contacted, and for whom information was available, 
84% responded to outreach efforts, which represents a very substantial increase 
over the 10% that is typical in the industry. Among respondents, enrollment rates 
ranged from 14% to 40%. cOnclusiOns: For all participating sites, querying EHR 
data proved to be an effective means of identifying eligible patients. Furthermore, 
